OLMA Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. (OLMA) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.70 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.0% since its last earnings release on November 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.